Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / EDRN Breast and Ovary Cancer CVC, Study 1: Preliminary validation of breast cancer early detection biomarker candidates from our WHI discovery project

EDRN Breast and Ovary Cancer CVC, Study 1: Preliminary validation of breast cancer early detection biomarker candidates from our WHI discovery project

371

No involved investigator sites defined.

>3000
Proteomics
Breast and Gynecologic Cancers Research
3

To identify promising candidate plasma early detection biomarkers specific to different molecular subtypes of breast cancer using preclinical specimens from the Women’s Health Initiative.

1.   Conduct a second screen of the most promising breast cancer early detection biomarkers to identify the candidates most suitable for validation. 2.   Validate the top 50 novel early detection biomarkers in an independent sample for breast cancer overall and for several breast cancer subtypes.
Antibody array

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.

Announcement 03/14/2017

Thank you to everyone who made the March 2017 EDRN Steering Committee Meeting a success. The next EDRN Steering Committee Meeting will be on September 12-14, 2018, in Seattle, WA.

Announcement 01/30/2017

Please visit http://www.compass. fhcrc.org/meeting/reg_edrn/edrnsc.aspx for information and to register for the 31st EDRN Steering Committee Meeting in Tempe, AZ, from March 6-9, 2017.